Clinical trials: Chronic Obstructive Pulmonary
Pulmonary Disease, Chronic Obstructive
A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients
GSK961081 has previously been administered to healthy subjects in a nebulised formulation and the first part of this study which will be conducted in healthy subjects proposes to bridge the change from nebulised to DPI…
- Trial name
- NCT00478738
- Testing
- GSK961081
- Where
- 5 sites in Germany, South Africa
- Volunteers
- 82 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium…
- Trial name
- NCT05127304
- Testing
- Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol
- Where
- United States
- Volunteers
- 11,316 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe…
- Trial name
- TITANIA (NCT05158387)
- Testing
- Tozorakimab
- Where
- 212 sites in United States, Australia and 18 more
- Volunteers
- 1,172 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC)…
- Trial name
- NCT01817764
- Testing
- Umeclidinium/vilanterol, Fluticasone propionate/salmeterol
- Where
- 59 sites in United States, Argentina and 5 more
- Volunteers
- 707 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients
It is hypothesised that there is a difference between the uptake of a radioactive substance ([18F]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
- Trial name
- NCT00472264
- Testing
- PET imaging
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Long-term Safety Study for GSK573719 in Japanese
The objective of this study is to evaluate the safety and tolerability of GSK573719 Inhalation Powder 125 mcg once-daily over 52 weeks in Japanese subjects with COPD.
- Trial name
- AC4115361 (NCT01702363)
- Testing
- GSK573719
- Where
- 20 sites in Japan
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
The rationale of this study is to conduct a summative (i.e., validation) usability test of Ciprofloxacin Dry Powder for Inhalation (DPI) and the associated Instructions for Use.
- Trial name
- NCT02661438
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bayer
Constipation
A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation
Constipation is common in the general population, especially in women and in the elderly. Hard stool is a complaint often associated with constipation, which suggests that stool softening would provide a major benefit in the…
- Trial name
- NCT02073006
- Testing
- Natural Fibre Supplement
- Where
- Ireland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials
Chronic Obstructive Pulmonary Disease (COPD)
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
- Trial name
- NCT01712516
- Testing
- QVA149, QAB149, NVA237
- Where
- 95 sites in United States, Colombia and 7 more
- Volunteers
- 1,001 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Pulmonary Disease, Chronic Obstructive
Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers
The aim of the study is to measure the inspiratory flow that the different patient groups (asthmatic children, adults and elderly, as well as chronic obstructive pulmonary disease (COPD) patients) generate through empty Easyhaler…
- Trial name
- PIFECO (NCT00984906)
- Testing
- Empty inhalers
- Where
- 4 sites in Finland, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Orion Corporation, Orion Pharma
Chronic Obstructive Pulmonary Disease
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
- Trial name
- NCT00640484
- Testing
- carmoterol (CHF 4226), salmeterol
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers
This study will be carried out in healthy volunteers with the primary objective to evaluate the pharmacokinetic interaction between Glyco and Formoterol administered using a pressurised metered dose inhaler (pMDI).
- Trial name
- TRIPLE 1 (NCT01398111)
- Testing
- Glycopyrrolate + Formoterol, Glycopyrrolate, Formoterol
- Where
- Belgium
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a…
- Trial name
- NCT04072887
- Testing
- QBW251, COPD maintenance background therapy
- Where
- 148 sites in United States, Argentina and 24 more
- Volunteers
- 974 people
- Sponsor
- Novartis Pharmaceuticals
Wheezing, Reactive Airway Disease
A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
The primary objective of this study is to evaluate budesonide levels in the blood following inhalation of single doses of VR647 Inhalation Suspension in children with wheezing, reactive airway disease or mild asthma using a…
- Conditions
- Wheezing, Reactive Airway Disease, Mild Asthma
- Trial name
- NCT03421730
- Testing
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Vectura Limited
Chronic Obstructive Pulmonary Disease
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease
- Trial name
- NCT07464587
- Testing
- TQC3721 Suspension for Inhalation
- Where
- 54 sites in China
- Volunteers
- 800 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
The purpose of this study is to evaluate the dose-response relationship of different doses of CHF6001 and to identify the optimal dose (s) in terms of benefit/risk ratio for further development in the target patient population.
- Trial name
- PIONEER (NCT02986321)
- Testing
- CHF6001, Budesonide
- Volunteers
- 1,130 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Post-authorisation observational study to assess the evolution in normal clinical practice of patients recently diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML), depending on the moment…
- Trial name
- NCT02085798
- Testing
- Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
- Where
- 50 sites in Spain
- Volunteers
- 503 people
- Sponsor
- Celgene
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
PT003 MDI Dose Confirmation Study
The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01349816
- Testing
- PT003, PT001, PT005
- Where
- 13 sites in United States
- Volunteers
- 185 people
- Sponsor
- Pearl Therapeutics, Inc.